Funding for this research was provided by:
Received: 17 May 2019
Accepted: 8 November 2019
First Online: 2 December 2019
Ethics approval and consent to participate
: The study was approved by independent ethics committees or institutional review boards at each study site and conducted in accordance with ethical principles outlined in the current Declaration of Helsinki and consistent with International Conference on Harmonisation Good Clinical Practice and Good Epidemiology Practices, along with all applicable local regulatory requirements. All patient data were deidentified and complied with patient confidentiality requirements.
: Not applicable.
: VS is a consultant for AbbVie, Amgen, AstraZeneca, BMS, Celgene, Genentech, GSK, Janssen, Eli Lilly, Novartis, Pfizer, Regeneron, Sanofi, and UCB, and is involved in advisory boards for AbbVie, Amgen, AstraZeneca, BMS, Celgene, Genentech, GSK, Janssen, Eli Lilly, Novartis, Pfizer, Regeneron, Sanofi, and UCB.MS is a consultant for AbbVie, BMS, Eli Lilly, JNJ, and UCB, and is a member of the speaker bureau for AbbVie and BMS.JP is a consultant for AbbVie, Amgen, BMS, Celltrion, GSK, Eli Lilly, Merck, Novartis, Pfizer, Roche, Sanofi, Sandoz, and UCB.NT, AF, SM, AP, and MF are employees of AbbVie and may own AbbVie stock or stock options.AG is a former employee of AbbVie and may own AbbVie stock or stock options.YS is an employee of Analysis Group Inc., which received consulting fees from AbbVie for this study.